Mein Warenkorb

ENPP3

ENPP3 Molekülinformation

Englischer NameEctonucleotide pyrophosphatase/phosphodiesterase family member 3Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel4Target-AliasEC:3.1.4.1,E-NPP 3,PD-Ibeta,NPPase,CD203c,PDNP3,Phosphodiesterase I/nucleotide pyrophosphatase 3,Nucleotide diphosphatase,ENPP3,DJ914N13.3 (Phosphodiesterase I/Nucleotide Pyrophosphatase 3),Phosphodiesterase-I Beta,Phosphodiesterase I Beta,CD203c Antigen,Gp130RB13-6,NPP3,B10,Ectonucleotide pyrophosphatase/phosphodiesterase family member 3,Ectonucleotide Pyrophosphatase/Phosphodiesterase 3,DJ1005H11.3 (Phosphodiesterase I/Nucleotide Pyrophosphatase 3),EC:3.6.1.9
Höchste Forschungs- und EntwicklungsphasePhase 1 Clinical
Englischer NameEctonucleotide pyrophosphatase/phosphodiesterase family member 3
Target-AliasEC:3.1.4.1,E-NPP 3,PD-Ibeta,NPPase,CD203c,PDNP3,Phosphodiesterase I/nucleotide pyrophosphatase 3,Nucleotide diphosphatase,ENPP3,DJ914N13.3 (Phosphodiesterase I/Nucleotide Pyrophosphatase 3),Phosphodiesterase-I Beta,Phosphodiesterase I Beta,CD203c Antigen,Gp130RB13-6,NPP3,B10,Ectonucleotide pyrophosphatase/phosphodiesterase family member 3,Ectonucleotide Pyrophosphatase/Phosphodiesterase 3,DJ1005H11.3 (Phosphodiesterase I/Nucleotide Pyrophosphatase 3),EC:3.6.1.9
Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel4
Höchste Forschungs- und EntwicklungsphasePhase 1 Clinical

ENPP3 Molekülhintergrund

The human NPP family contains seven members which can be classified into two groups according to their substrate preferences. The first class comprises the nucleotide-degrading proteins NPP1, 3 and 4. NPP3 (CD203c, ENPP3) is expressed in multiple organs, including on epithelial and mucosal surfaces, and notably on basophils and mast cells. Activation of basophils by antigen-bound IgE leads to release of inflammatory mediators and rapid upregulation of NPP3 to the cell surface. This protein is in fact a common marker for diagnosing allergen sensitivity with patient basophils by flow cytometry. Basophils and mast cells mediate the response to certain pathogens, as well as acute and chronic allergic reactions. Following activation, these cells release ATP, which further stimulates them in an autocrine manner. NPP3 upregulation serves to degrade ATP and suppress chronic allergic inflammation (but not the acute response).

ENPP3 Molekülalias

ENPP3,CD203c,NPP3,E-NPP3,PD-Ibeta,NPPase,PDNP3

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
XmAb-819XmAb-819Phase 1 ClinicalXencor IncCarcinoma, Renal Cell; Kidney Neoplasms
Details
JNJ-89862175JNJ-89862175Phase 1 ClinicalJanssen Research & Development LlcSolid tumours
Details
ALY-301ALY-301; GTX-B001Phase 1 ClinicalAlys Pharmaceuticals IncChronic Urticaria; Symptomatic Dermographism; Urticaria
Details
JNJ-87890387JNJ-87890387Phase 1 ClinicalJanssen Research & Development LlcNeoplasms; Solid tumours
Details
  • Molekülinformation
  • Produktliste
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns